Impact of Small or Non-Small Vessel Disease to Drug-Coated Balloon Angioplasty for the Treatment of De Novo Coronary Artery Lesions: Insights From the REC-CAGEFREE I Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - SMT; Philips; Xeltis; Merillife; Novartis